Dr. Noel W. Clarke presented  “Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.

 

 

Keywords: metastatic prostate cancer, bone targeted agents, Denosumab, Bisphosphonates, Radium-223, TRAPEZE, ALSYMPCA

How to cite: Clarke, Noel. “Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223” Grand Rounds in Urology. October 14-16, 2016. Accessed Aug 2019. https://grandroundsinurology.com/bone-targeted-agents-metastatic-prostate-cancer-denosumab-bisphosphonates-radium-223

This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.